Skip to content
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Search
2020-05-20T12:01:36-05:00
Search
Search by Abstract Number, Title, Keyword, or Authors
Search by...
All
Authors and Affiliations
Title
Abstract Number
Keyword
Category
All
Clinical Vignettes
Innovations
Research
Sub-Category
(Optional)
Select Sub-Category...
Adult
Communication
Consultative Medicine
Education
Finalist
Geriatrics
Other
Outcomes Research
Patient Safety
Pediatric
Pediatrics
Perioperative
Quality Improvement
Technology in Hospital Medicine
Transitions of Care
Translating Research into Practice
Uncategorized
Value in Hospital Medicine
Winners
Session Type
Select Session Type...
Oral Presentations
Plenary Presentations
Meeting
All Meetings
SHM Converge 2023
SHM Converge 2022
SHM Converge 2021
Hospital Medicine 2020, Virtual Competition
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Hospital Medicine 2015, March 29-April 1, National Harbor, Md.
Hospital Medicine 2014, March 24-27, Las Vegas, Nev.
Hospital Medicine 2013, May 16-19, National Harbor, Md.
Hospital Medicine 2012, April 1-4, San Diego, Calif.
Hospital Medicine 2011, May 10-13, Dallas, Texas.
Hospital Medicine 2010, April 8-11, Washington, D.C.
Hospital Medicine 2009, May 14-17, Chicago, Ill.
Hospital Medicine 2008, April 3-5, San Diego, Calif.
Hospital Medicine 2007, May 23-25, Dallas, Texas
Hospital Medicine 2006, May 3-5, Washington, D.C.
Search Results for
DOACs
Abstract Number: B9
COMPARING THE SAFETY AND EFFECTIVENESS OF APIXABAN AND WARFARIN FOR ACUTE VENOUS THROMBOEMBOLISM IN PATIENTS WITH END STAGE RENAL DISEASE
SHM Converge 2022
Background: Patients with end stage renal disease (ESRD) are at significantly increased risk for both thrombosis and bleeding relative to those with normal renal function, which makes anticoagulation particularly challenging. Evidence suggests that rivaroxaban and dabigatran are associated with a higher risk of bleeding in ESRD patients. To date, no large national cohort studies have […]
Abstract Number: E9
META-ANALYSIS ON SAFETY AND EFFICACY OF DIRECT ORAL ANTICOAGULANTS IN PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN MYELOPROLIFERATIVE NEOPLASMS
SHM Converge 2022
Background: Arterial (3-fold) and venous (10-fold) thromboembolism are more common in myeloproliferative neoplasm (MPN) than general population with rates as high as 50% in polycythemia vera (PV) and essential thrombocythemia (ET).1,2 While primary prophylaxis with aspirin is not debated for prevention of arterial and venous thromboembolism, the choice of anticoagulant for secondary prophylaxis and treatment […]
Page load link
Go to Top